ClinicalTrials.gg
Not yet recruitingNCT07949240Updated Nov 19, 2026

Epidural Spinal Cord Stimulation for Motor Recovery After Spinal Cord Injury: A Pilot Study

An interventional study of Epidural Spinal Cord Stimulation (scES) and Activity-Based Rehabilitation (ABT) in Spinal Cord Injuries (Complete and Incomplete), sponsored by Dr. Gabriel Zeilig. Not yet recruiting at 1 site in Israel. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-11-19.

Sponsored by Dr. Gabriel Zeilig · Not applicable, Interventional, and Treatment

How we know

Updated Nov 19, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
10
Allocation
Not applicable
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 12 studies in Spinal Cord Injuries with a site in Israel — 6 open to participants now, 6 under way, none of them phase 3. Spinal Cord Injuries · Israel.

Planned enrollment
9th of 10
10 · median 55
Started
2027
with 1 other
No phase
7 of 12
6 open now
Registered
11th of 12
by date
Lead sponsor
2 of 12
Dr. Gabriel Zeilig

Among the 12 studies in Spinal Cord Injuries with a site in Israel, this one is the 9th largest by planned enrollment of the 10 interventional ones that give a count, is one of 2 that started in 2027, is one of 7 with no phase, and was the 11th registered.

Spinal Cord Injuries

2,032 studies on the registry are indexed under Spinal Cord Injuries; 542 are open to participants now.

Browse Spinal Cord Injuries studies →

Open to participants now

6 of the 12 studies in Spinal Cord Injuries with a site in Israel are open now. Recruiting first, the newest first:

All 6 open studies →

A study can be open while its sites in Israel have not opened yet or have stopped. Only those recruiting at a site in Israel →

Who these studies take

Of the 374 Spinal Cord Injuries studies recruiting now, 167 (45%) set no upper age limit and 156 (42%) stop at 75 or younger; 40 take children under 18; 52 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies in Spinal Cord Injuries with a site in Israel, or all of them as a file.
02

Study summary

This pilot study aims to evaluate the safety and feasibility of epidural spinal cord stimulation (scES) combined with intensive rehabilitation in individuals with chronic spinal cord injury (SCI). The study will enroll up to 10 adults with spinal cord injury who are unable to walk independently in the community.

Participants will undergo surgical implantation of an epidural spinal cord stimulation system, followed by individualized stimulation programming and 80 sessions of activity-based rehabilitation focusing on voluntary lower extremity movements, standing, and stepping.

The primary objectives are to assess the safety of the implantation and stimulation procedures and the feasibility of implementing the rehabilitation protocol. Secondary objectives include evaluating potential changes in motor function, autonomic function, psychological well-being, and quality of life.

Participants will be followed for approximately 12 months, with repeated clinical and functional assessments throughout the study.

Read the detailed description

This prospective, single-arm, interventional pilot study will enroll up to 10 adults aged 18-65 years with chronic spinal cord injury at least 12 months post-injury. The study will be conducted at Sheba Medical Center.

Following screening and baseline assessments, eligible participants will undergo surgical implantation of an epidural electrode array (Medtronic Specify 5-6-5) and an implantable pulse generator (Medtronic Intellis). The electrode array will be positioned over the lumbosacral spinal cord to facilitate motor activation of the lower extremities.

Approximately 1-2 weeks after implantation, participants will undergo neurophysiological mapping to identify individualized electrode configurations and stimulation parameters. The StimX research system will be used to program stimulation patterns targeting voluntary movement, standing, and stepping.

Participants will then complete 80 sessions of intensive, task-specific rehabilitation combined with epidural stimulation, delivered approximately five days per week over 3-6 months. Training will include voluntary lower extremity movements, standing, stepping, transfers, and other functional tasks, with progression tailored to each participant's abilities and responses.

Clinical and functional assessments will be conducted at baseline and after 20, 40, 60, and 80 training sessions. Participants will be followed for approximately 12 months after implantation.

The primary outcomes will focus on safety and feasibility, including serious adverse events related to surgery or the device, recruitment and retention, successful stimulation mapping, and completion of planned training sessions.

Secondary assessments will examine voluntary motor control, standing and stepping performance, neurological status, muscle activation using electromyography (EMG), cardiovascular and other autonomic functions, psychological symptoms, and quality of life.

The study is designed primarily to establish safety and feasibility and to generate preliminary data to inform future clinical studies.

03

Conditions studied

  • Spinal Cord Injuries (Complete and Incomplete)

Keywords

  • Epidural spinal cord stimulation
  • Spinal cord rehabilitation
  • Activity-based therapy
  • Motor recovery
  • Implantable neurostimulation
  • Neuromodulation
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

**Inclusion Criteria:**

  1. Adults aged 18-65 years.
  2. Chronic, stable traumatic or non-traumatic spinal cord injury (SCI), at least 12 months post-injury.
  3. Cervical or thoracic (>T10) SCI, with the ability to voluntarily move at least three joints below the injury level.
  4. Non-community ambulator.
  5. Medically stable and able to participate in intensive rehabilitation.
  6. Able to understand study procedures and provide in Hebrew, English, or Arabic.
  7. For women of : negative pregnancy test.

**Exclusion Criteria:**

  1. Active systemic infection.
  2. Neurological disease other than SCI, including multiple sclerosis, motor neuron disease (e.g., ALS), peripheral neuropathy, or another progressive neurological disease.
  3. Coagulopathy or inability to safely discontinue anticoagulation for surgery.
  4. Known allergy to device materials.
  5. Ventilator dependence.
  6. Untreated or unstable fracture or pressure ulcer.
  7. Untreated psychiatric disorder or ongoing drug abuse.
  8. Cardiac, respiratory, bladder, renal, or other medical disorder that may interfere with the study.
  9. Skeletal muscle Botox injections within the previous 6 months.
  10. Any implanted pump (e.g., baclofen pump or pain pump).
  11. Unable or unwilling to discontinue anti-spasticity medications.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
10 participants (estimated)

Study arms

  • Experimental
    Epidural Spinal Cord Stimulation + Activity-Based Rehabilitation

    All participants will undergo surgical implantation of an epidural spinal cord stimulation system, followed by individualized stimulation mapping and programming. Participants will then receive 80 sessions of activity-based rehabilitation combined with epidural stimulation, focusing on voluntary lower extremity movements, standing, and stepping. Follow-up will continue for approximately 12 months after implantation.

    Device: Epidural Spinal Cord Stimulation (scES) · Other: Activity-Based Rehabilitation (ABT)

Interventions

  • DeviceEpidural Spinal Cord Stimulation (scES)

    Surgical implantation of a Medtronic Specify 5-6-5 epidural electrode array over the lumbosacral spinal cord and a Medtronic Intellis implantable pulse generator. Stimulation will be individually programmed using the StimX research system. Electrode configurations and stimulation parameters will be optimized through neurophysiological mapping to facilitate voluntary lower extremity movements, standing, and stepping.

  • OtherActivity-Based Rehabilitation (ABT)

    Individualized, task-specific rehabilitation combined with epidural spinal cord stimulation. Training will include voluntary lower extremity movements, standing, stepping, sit-to-stand practice, transfers, and other functional tasks. Participants will complete 80 training sessions over approximately 3-6 months, generally five sessions per week, with approximately one hour of active training per session.

06

What researchers measure

Primary outcomes

  1. Serious Adverse Events

    * Title:\*\* Percentage of Participants Experiencing Device- or Surgery-Related Serious Adverse Events * Description:\*\* Percentage of implanted participants experiencing at least one serious adverse event related to the surgical procedure or implanted stimulation system. Serious adverse events will be recorded and assessed for their relationship to the procedure or device. * Time Frame:\*\* From implantation through 12 months after implantation.

    Time frame: From implantation through 12 months after implantation.

  2. Participant Recruitment Rate

    Number of participants enrolled per month during the recruitment period.

    Time frame: During the recruitment period (anticipated up to 12 months).

  3. Retention at 6 Months

    Percentage of enrolled participants who remain in the study at the 6-month follow-up.

    Time frame: 6 months after implantation.

  4. Retention at 12 Months

    Percentage of enrolled participants who remain in the study at the 12-month follow-up

    Time frame: 12 months after implantation.

  5. Stimulation Mapping

    Number of implanted participants who complete the planned postoperative neurophysiological mapping procedures to identify individualized electrode configurations and stimulation parameters

    Time frame: During initial postoperative mapping, approximately 1-3 weeks after implantation

  6. Number of Rehabilitation Training Sessions Completed

    Number of completed rehabilitation training sessions per participant out of the 80 planned sessions combining activity-based rehabilitation with epidural spinal cord stimulation.

    Time frame: During the rehabilitation period, approximately 3-6 months after initiation of training

Secondary outcomes

  1. Change in Neuromuscular Recovery Scale (NRS) Standing Task Rating

    Change in standing performance assessed using the standing task rating of the Neuromuscular Recovery Scale (NRS), which evaluates motor performance and the level of assistance required without relying on compensatory movement strategies

    Time frame: Baseline (before implantation), after 40 training sessions (up to 3 months after training initiation), and after 80 training sessions (up to 6 months after training initiation).

  2. Change in Neuromuscular Recovery Scale (NRS) Stepping Task Rating

    Change in stepping performance assessed using the stepping task rating of the Neuromuscular Recovery Scale (NRS).

    Time frame: Baseline (before implantation), after 40 training sessions (up to 3 months after training initiation), and after 80 training sessions (up to 6 months after training initiation).

  3. Neurological Motor Function

    Change in neurological motor function assessed using the ISNCSCI examination. The total motor score ranges from 0 to 100, with higher scores indicating better motor function

    Time frame: Baseline (before implantation), after 40 training sessions (up to 3 months after training initiation), and after 80 training sessions (up to 6 months after training initiation).

  4. Maximum Assisted Standing Duration Under Epidural Stimulation

    Maximum duration in seconds that a participant can maintain assisted standing while receiving epidural spinal cord stimulation.

    Time frame: After 40 training sessions (up to 3 months after training initiation) and after 80 training sessions (up to 6 months after training initiation). העתק

  5. Depression (PHQ-9)

    Change in depressive symptoms assessed using the 9-item Patient Health Questionnaire. Total scores range from 0 to 27, with higher scores indicating greater depressive symptom severity

    Time frame: Baseline (before implantation), after 40 training sessions (up to 3 months after training initiation), and after 80 training sessions (up to 6 months after training initiation).

  6. Anxiety (GAD-7)

    Change in anxiety symptoms assessed using the 7-item Generalized Anxiety Disorder scale. Total scores range from 0 to 21, with higher scores indicating greater anxiety symptom severity

    Time frame: Baseline (before implantation), after 40 training sessions (up to 3 months after training initiation), and after 80 training sessions (up to 6 months after training initiation).

  7. PTSD (PCL-5)

    Change in self-reported post-traumatic stress symptoms assessed using the PTSD Checklist for DSM-5. Total scores range from 0 to 80, with higher scores indicating greater symptom severity.

    Time frame: Baseline (before implantation), after 40 training sessions (up to 3 months after training initiation), and after 80 training sessions (up to 6 months after training initiation).

  8. PTSD (CAPS-5)

    Change in clinician-rated post-traumatic stress symptom severity assessed using the CAPS-5. Total severity scores range from 0 to 80, with higher scores indicating greater symptom severity.

    Time frame: Baseline (before implantation), after 40 training sessions (up to 3 months after training initiation), and after 80 training sessions (up to 6 months after training initiation).

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for May 2027; primary completion for Dec 2028, 19 months later.

Of 791 non-industry interventional studies with no phase under Spinal Cord Injuries, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 65. This study's planned 19 months is below that.

Counting every sponsor, half of 840 studies reached it within 36 months; a quarter within 17 and three quarters within 64.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 8, 2026
First posted
Nov 19, 2026
StartEst.
May 1, 2027
Primary completionEst.
Dec 1, 2028
CompletionEst.
Dec 1, 2028
Last update
Nov 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 19, 2026
Show all 1 update
  1. Nov 19, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07949240
Lead sponsor
Dr. Gabriel Zeilig
Responsible party
Dr. Gabriel Zeilig (Principal Investigator, Sheba Medical Center) — Sponsor-investigator
First posted
Nov 19, 2026
Start date
May 1, 2027 (estimated)
Primary completion
Dec 1, 2028 (estimated)
Completion
Dec 1, 2028 (estimated)
Last update
Nov 19, 2026

Study contacts

Amihai Gottlieb, Ph.D
Contact
amihai.gottlieb@gmail.com
+972543323180

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion